Información del artículo
Resumen
En la Digestive Disease Week (DDW) 2008, se han presentado datos importantes sobre la historia natural, el diagnóstico y el tratamiento tanto de la enfermedad por reflujo gastroesofágico (ERGE) como del esófago de Barrett. Desde el punto de vista diagnóstico, ha destacado el análisis crítico del perfil sintomático en la práctica clínica y por la consolidación de la impedanciometría como técnica diagnóstica en la ERGE. En cuanto al tratamiento, destacan los nuevos datos sobre la utilidad y la seguridad de la ablación mediante radiofrecuencia en el tratamiento de las displasias de alto y bajo grado sobre esófago de Barrett.
Palabras clave:
Enfermedad por reflujo gastroesofágico
Esofagitis
Esófago de Barrett
Adenocarcinoma esofágico
Tratamiento
Abstract
In Digestive Disease Week (DDW) 2008, important data were presented on the natural history, diagnosis and treatment of both gastroesophageal reflux disease (GERD) and Barrett's esophagus. Contributions to diagnosis consisted of the importance of critical analysis of symptom profile in clinical practice and consolidation of impedanciometry as a diagnostic technique in GERD. Treatment highlights consisted of new data on the safety and utility of radiofrequency ablation in the treatment of high- and low-grade dysplasia in Barrett's esophagus.
Key words:
Gastroesophageal reflux disease
esophagitis
Barrett's esophagus
esophageal adenocarcinoma
treatment
El Texto completo está disponible en PDF
Bibliografía
[1.]
E. Rey, F.R. Artalejo, A.A. Sanchez, M. Paz-Rubio.
Incidence of gastroesophageal reflux symptoms and remission rate in general population.
Gastroenterology, 134 (2008), pp. A324
[2.]
P. Malfertheiner, M. Nocon, M.R. Hoecker, D. Jaspersen, J. Labenz, H.R. Koelz, et al.
How does GERD evolve during a 5-year follow-up period? The progerd study.
Gastroenterology, 134 (2008), pp. A592-A593
[3.]
J. Ronkainen, P. Aro, T. Storskrubb, N.J. Talley, M. Vieth, T. Lind, et al.
Natural history of NERD in the general population, the kalixanda study.
Gastroenterology, 134 (2008), pp. A74-A75
[4.]
T. Shimatani, S. Hirokawa, K. Hamai, Y. Tawara, M. Matsumoto, A. Furukawa, et al.
H. pylori infection is not involved in the pathogenesis of erosive and non-erosive reflux disease in a young population: studies from a health check-up program of 678 consecutive Japanese subjects in their 20s.
Gastroenterology, 134 (2008), pp. A594
[5.]
E. Rey, F.R. Artalejo, M.A. Herraiz, A.A. Sanchez, C. Almansa, M. Escudero, et al.
Atypical symptoms of gastroesophageal reflux during pregnancy.
Gastroenterology, 134 (2008), pp. A39
[6.]
G. Cadiot, P.H. Delaage, C. Fabry, P. Barthelemy.
Sleep disturbance associated with gastro-oesophageal reflux disease (GORD): Frequency and evolution with treatment according to patients.
Gastroenterology, 134 (2008), pp. A169
[7.]
W.D. Chey, R. Mody, L. Chen, S. Kothari, B. Persson, E. Wu, et al.
Nighttime symptoms and sleep impairment among patients with gastroesophageal reflux disease (GERD) receiving prescription (Rx) proton pump inhibitors (PPIs).
Gastroenterology, 134 (2008), pp. A323-A324
[8.]
R. Salvador, F.A. Herbella, A. Dubecz, M. Polomsky, T. Trus, C.E. Jones, et al.
Association of gastroesophageal reflux and O2 desaturation in patients with GERD; a novel study of simultaneous 24-hour impedance-pH and continuous pulse-oximetry.
Gastroenterology, 134 (2008), pp. A865
[9.]
G.J. Holtmann, R.H. Hunt, J.E. Tack, A.K. Korell, H. Doerfler, P.H. Katelaris.
Symptom relief assessed by reflux questionnaire (RequestTM): A superior clinical endpoint compared to investigatorassessed heartburn?.
Gastroenterology, 134 (2008), pp. A176
[10.]
N. Vakil, J. Dent, R. Jones, K. Halling, T. Lind, O. Junghard.
The accuracy and predictors of a clinical diagnosis of GERD by family practitioners and gastroenterologists.
Gastroenterology, 134 (2008), pp. A598
[11.]
E. Savarino, D. Pohl, L. Sconfienza, P. Zentilin, P. Dulbecco, R. Tutuian, et al.
Prevalence of dyspepsia symptoms in patients with Non Erosive Reflux Disease (NERD) subclassified using 24-hour ambulatory intraluminal pH-impedance.
Gastroenterology, 134 (2008), pp. A716
[12.]
M. Ponce, X. Calvet, M. Gallach, J. Ponce.
Prevalencia de esofagitis grave en España.
Gastroenterol Hepatol, 31 (2008), pp. 150
[13.]
P. Bytzer, R. Jones, N. Vakil, O. Junghard, T. Lind, J. Dent.
Evaluation of the proton pump inhibitor (PPI) test for the diagnosis of GERD: Results from the diamond study.
Gastroenterology, 134 (2008), pp. A100
[14.]
A. Niklasson, L.M. Lindstrom, M. Simren, G. Lindberg, E. Bjornsson.
Dyspeptic symptom development after discontinuation of a proton pump inhibitor: Clinical importance of acid-rebound.
Gastroenterology, 134 (2008), pp. A112
[15.]
H. Monnikes, H. Doerfler, H. Schmitt, P. Berghoefer, R. Heading.
Is the response of GERD patients to PPI therapy affected by the presence of IBS-Like symptoms?.
Gastroenterology, 134 (2008), pp. A126
[16.]
J. Wu, Y. Chan, K.K. Tsoi, V.W. Wong, L. Lai, G. Wong, et al.
On-demand versus daily proton pump inhibitor (PPI) for maintenance treatment of gastroesophageal reflux disease (GERD): A double blind, double dummy, randomized placebo controlled trial and cost-effectiveness analysis.
Gastroenterology, 134 (2008), pp. A126
[17.]
T. Furuta, M. Sugimoto, C. Kodaira, M. Nishino, M. Yamade, M. Ikuma, et al.
Cyp2c19 genotype is a useful marker of optimal dose of a proton pump inhibitor in the maintenance therapy of symptomatic gastroesophageal reflux diseases.
Gastroenterology, 134 (2008), pp. A172
[18.]
W.D. Chey, R. Mody, S. Kothari, E. Wu, L. Chen, B. Persson, et al.
Are proton pump inhibitors (PPIs) sufficient in controlling symptoms of gastro-esophageal reflux disease (GERD)? A community-based US survey study.
Gastroenterology, 134 (2008), pp. A325
[19.]
M. Bajbouj, V. Becker, R.M. Schmid, A. Meining.
High-dose esomeprazole in combination with baclofen in the treatment of symptomatic refractory gastroesophageal reflux disease –a pH-metry/impedance controlled study.
Gastroenterology, 134 (2008), pp. A173
[20.]
T. Navarro-Rodriguez, A. Gasiorowska, Y. Ibuki, R. Dickman, B. Moty, J. Powers, et al.
The effect of Johrei (energy healing) versus wait-list on symptoms of patients with functional chest pain (Fcp) of presumed esophageal origin –a randomized trial.
Gastroenterology, 134 (2008), pp. A721
[21.]
R. Dickman, E. Schiff, A. Holland, C. Wright, S.R. Sarela, B. Han, et al.
Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn.
Aliment Pharmacol Ther, 26 (2007), pp. 1333-1344
[22.]
T. Shimatani, S. Tazuma, M. Inoue.
Comparison of acid-suppressive effects of three brands of generic lansoprazole with original lansoprazole: Pharmacodynamic equivalence is not necessarily guaranteed by pharmacokinetic bioequivalence tests.
Gastroenterology, 134 (2008), pp. A478
[23.]
T. Shimatani, M. Inoue, T. Kuroiwa, J. Xu, H. Mieno, S. Tazuma.
Acid-suppressive effects of generic omeprazole: comparison of three brands of generic omeprazole with original omeprazole.
Dig Liver Dis, 38 (2006), pp. 554-559
[24.]
R.F. Esquivel, V. Boolchand, N. Kumar, L. Camargo, J.L. Kim, R. Fass, et al.
The prevalence of Barrett's esophagus in veteran patients with and without GERD symptoms undergoing outpatient colonoscopy.
Gastrointest Endosc, 67 (2008), pp. AB172
[25.]
M. Sikkema, M. Kerkhof, E.W. Steyerberg, H. Van Dekken, A. Van Vuuren, W.A. Bode, et al.
Prospective multicenter study on the incidence of neoplastic progression in Barrett esophagus patients.
Gastrointest Endosc, 67 (2008), pp. AB75
[26.]
P.J. De Jonge, M. Van Blankenstein, C.W. Looman, M.K. Casparie, G.A. Meijer, E.J. Kuipers.
Trends in the incidence of Barrett's esophagus in the Netherlands 1991-2006.
Gastroenterology, 134 (2008), pp. A39
[27.]
H.B. El-Serag, P. Richardson.
The extent and duration of using acid reducing medications in patients with Barrett's esophagus.
Gastroenterology, 134 (2008), pp. A39
[28.]
H.B. El-Serag, P. Richardson.
PPI use and the risk of esophageal cancer in patients with BE: A nested case-control study.
Gastroenterology, 134 (2008), pp. A39
[29.]
N.J. Shaheen, P. Sharma, B.F. Overholt, C.J. Lightdale, H.C. Wolfsen, R.E. Sampliner, et al.
A randomized, multicenter, shamcontrolled trial of radiofrequency ablation (RFA) for subjects with Barrett's esophagus (BE) containing dysplasia: Interim results of the aim dysplasia trial.
Gastroenterology, 134 (2008), pp. A37
[30.]
N.J. Shaheen, H.C. Wolfsen, R.H. Hawes, R.I. Rothstein, S.J. Spechler, J. Galanko, et al.
Impact of Barrett's esophagus containing dysplasia on patient quality of life: Interim results of a randomized, sham-controlled trial of radiofrequency ablation (AIM dysplasia trial).
Gastroenterology, 134 (2008), pp. A323
[31.]
C.J. Lightdale, B.F. Overholt, K.K. Wang, H. Mashimo, V.K. Sharma, D.E. Fleischer, et al.
Predictors and quantitative assessment of incomplete response after radiofrequency ablation for dysplastic Barrett's esophagus: Analysis of randomized sham-controlled clinical trial (The AIM dysplasia trial).
Gastrointest Endosc, 67 (2008), pp. AB182
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
